Beigene (NASDAQ:ONC) Upgraded at Bank of America

Bank of America upgraded shares of Beigene (NASDAQ:ONC) from a neutral rating to a buy rating in a report published on Monday, MarketBeat reports. They currently have $320.00 price target on the stock, up from their previous price target of $207.00.

Separately, Macquarie lifted their target price on shares of Beigene from $259.00 to $313.00 and gave the stock an “outperform” rating in a research note on Friday, February 28th.

Beigene Trading Up 1.9 %

Shares of NASDAQ:ONC opened at $262.21 on Monday. The firm has a market cap of $25.66 billion, a PE ratio of -31.82, a price-to-earnings-growth ratio of 7.73 and a beta of 0.63. The company has a current ratio of 1.93, a quick ratio of 1.72 and a debt-to-equity ratio of 0.05. Beigene has a 52 week low of $126.97 and a 52 week high of $287.88.

Beigene (NASDAQ:ONC) last announced its earnings results on Thursday, February 27th. The company reported ($1.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.55). Beigene had a negative return on equity of 25.12% and a negative net margin of 25.94%. The firm had revenue of $1.13 billion for the quarter, compared to the consensus estimate of $1.09 billion. As a group, equities analysts expect that Beigene will post -5.82 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Beigene news, SVP Chan Henry Lee sold 1,202 shares of Beigene stock in a transaction on Friday, February 21st. The shares were sold at an average price of $258.04, for a total value of $310,164.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Xiaobin Wu sold 21,267 shares of Beigene stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $240.07, for a total transaction of $5,105,568.69. The disclosure for this sale can be found here. Insiders sold 891,950 shares of company stock valued at $229,290,847 over the last quarter. Insiders own 7.43% of the company’s stock.

Beigene Company Profile

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.